Lowering total plasma insulin-like growth factor I concentrations by way of a novel, potent, and selective growth hormone (GH) receptor antagonist, pegvisomant (B2036-peg), augments the amplitude of GH secretory bursts and elevates basal/nonpulsatile GH release in healthy women and men.

Veldhuis JD, Bidlingmaier M, Anderson SM, Wu Z, Strasburger CJ

The Journal of clinical endocrinology and metabolism1 Jul 2001Cited by 50 (Europe PMC)

PMID11443205DOI10.1210/jcem.86.7.7656PepBankPUB-11443205

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialMechanism
In healthy adults, pegvisomant reduced fasting IGF-I by 31% versus placebo at 84 h, from 276 +/- 42 to 190 +/- 20 microg/L (P = 0.006).
In plain wordsIn healthy adults, pegvisomant reduced fasting IGF-I versus placebo.
Peptide
Pegvisomant
Outcome
DecreaseFasting total IGF-I at 84 h
Study
n = 12
Comparator
Saline placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg · subcutaneousAs given in this study (human).
Measurements
Fasting total IGF-I at 84 h
276 microg/L
placebo (+/- 42)
Fasting total IGF-I at 84 h
190 microg/L
pegvisomant (+/- 20)
Reduction in fasting total IGF-I
31 percent
pegvisomant versus placebo
Source sentences
Summary
suppressed fasting total IGF-I concentrations by 31%, viz. from (mean +/- SEM) 276 +/- 42 (placebo) to 190 +/- 20 microg/L (pegvisomant; P = 0.006) 84 h after drug injection
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, we sampled blood at 10-min intervals for 10 h overnight in 8 men (aged 19-46 yr) and 4 women (aged 19-39 yr) to quantitate endogenous GH secretion and half-life 72 h after the prospective, randomly ordered, double blind, and within-subject cross-over administration of pegvisomant (1 mg/…
Report a problemFND-1144320501
02HumanRandomized controlled trialMechanism
In healthy adults, pegvisomant increased 10-h mean serum GH by 71% versus placebo, from 1.4 +/- 0.33 to 2.4 +/- 0.58 microg/L (P = 0.024).
In plain wordsIn healthy adults, pegvisomant increased mean GH versus placebo.
Peptide
Pegvisomant
Outcome
IncreaseMean serum GH
Study
n = 12
Comparator
Saline placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg · subcutaneousAs given in this study (human).
Measurements
10-h mean serum GH
1.4 microg/L
placebo (+/- 0.33)
10-h mean serum GH
2.4 microg/L
pegvisomant (+/- 0.58)
Increase in 10-h mean serum GH
71 percent
pegvisomant versus placebo
Source sentences
Summary
increased the 10-h mean serum GH concentration by 71% from 1.4 +/- 0.33 (placebo) to 2.4 +/- 0.58 (pegvisomant; P = 0.024)
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, we sampled blood at 10-min intervals for 10 h overnight in 8 men (aged 19-46 yr) and 4 women (aged 19-39 yr) to quantitate endogenous GH secretion and half-life 72 h after the prospective, randomly ordered, double blind, and within-subject cross-over administration of pegvisomant (1 mg/…
Report a problemFND-1144320502
03HumanRandomized controlled trialMechanism
In healthy adults, pegvisomant increased GH burst amplitude 2.1-fold versus placebo, from 0.13 +/- 0.032 to 0.27 +/- 0.076 microg/L.min (P = 0.0088).
In plain wordsIn healthy adults, pegvisomant increased GH burst amplitude versus placebo.
Peptide
Pegvisomant
Outcome
IncreaseGH secretory burst amplitude
Study
n = 12
Comparator
Saline placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg · subcutaneousAs given in this study (human).
Measurements
GH secretory burst amplitude
0.13 microg/L.min
first value reported (+/- 0.032)
GH secretory burst amplitude
0.27 microg/L.min
second value reported (+/- 0.076)
Increase in GH secretory burst amplitude
2.1 fold
pegvisomant versus placebo
Source sentences
Summary
augmented the amplitude of underlying GH secretory bursts by 2.1-fold (i.e. from 0.13 +/- 0.032 to 0.27 +/- 0.076 microg/L.min; P = 0.0088)
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, we sampled blood at 10-min intervals for 10 h overnight in 8 men (aged 19-46 yr) and 4 women (aged 19-39 yr) to quantitate endogenous GH secretion and half-life 72 h after the prospective, randomly ordered, double blind, and within-subject cross-over administration of pegvisomant (1 mg/…
Report a problemFND-1144320503
04HumanRandomized controlled trialMechanism
In healthy adults, pegvisomant increased basal GH secretion 2.5-fold versus placebo, from 2.3 +/- 0.77 to 5.07 +/- 1.8 microg/L.10 h (P = 0.022).
In plain wordsIn healthy adults, pegvisomant increased basal GH secretion versus placebo.
Peptide
Pegvisomant
Outcome
IncreaseBasal GH secretion
Study
n = 12
Comparator
Saline placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg · subcutaneousAs given in this study (human).
Measurements
Basal/nonpulsatile GH secretion rate
2.3 microg/L.10 h
first value reported (+/- 0.77)
Basal/nonpulsatile GH secretion rate
5.07 microg/L.10 h
second value reported (+/- 1.8)
Increase in basal/nonpulsatile GH secretion rate
2.5 fold
pegvisomant versus placebo
Source sentences
Summary
elevated the basal/nonpulsatile rate of GH secretion by 2.5-fold (from 2.3 +/- 0.77 to 5.07 +/- 1.8 microg/L.10 h; P = 0.022).
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, we sampled blood at 10-min intervals for 10 h overnight in 8 men (aged 19-46 yr) and 4 women (aged 19-39 yr) to quantitate endogenous GH secretion and half-life 72 h after the prospective, randomly ordered, double blind, and within-subject cross-over administration of pegvisomant (1 mg/…
Report a problemFND-1144320504
05HumanRandomized controlled trialMechanism
In healthy adults, pegvisomant-related IGF-I depletion did not alter GH pulse frequency, half-duration, interpulse interval, pulsatile release percentage, or GH half-life.
In plain wordsIn healthy adults, pegvisomant did not alter GH pulse characteristics or half-life versus placebo.
Peptide
Pegvisomant
Outcome
No significant changeGH pulse characteristics and half-life
Study
n = 12
Comparator
Saline placebo
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 mg/kg · subcutaneousAs given in this study (human).
Source sentences
Summary
In contrast, IGF-I depletion did not alter GH secretory pulse frequency, half-duration, interpulse interval, percentage of pulsatile GH release, or half-life of endogenous GH.
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, we sampled blood at 10-min intervals for 10 h overnight in 8 men (aged 19-46 yr) and 4 women (aged 19-39 yr) to quantitate endogenous GH secretion and half-life 72 h after the prospective, randomly ordered, double blind, and within-subject cross-over administration of pegvisomant (1 mg/…
Report a problemFND-1144320506

Studies that did not test the peptide alone1

In this study, Pegvisomant was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pegvisomant.

06HumanNot a test of Pegvisomant aloneObservational studyMechanism
In healthy adults given pegvisomant, increased GH burst amplitude correlated with falling IGF-I (r = 0.603; P = 0.038).
In plain wordsIn healthy adults given pegvisomant, increased GH burst amplitude was linked to falling IGF-I.
Peptide
Pegvisomant
Outcome
Not applicableGH burst amplitude association with IGF-I decline
Study
n = 12
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Measurements
Correlation between rise in GH burst amplitude and fall in plasma IGF-I
0.603 r
healthy adults after pegvisomant
Source sentences
Summary
The rise in the amplitude of GH secretory bursts correlated with the fall in plasma IGF-I concentrations (r = 0.603; P = 0.038).
1 context sentence(design, population, supporting numbers)
Summary · context
To this end, we sampled blood at 10-min intervals for 10 h overnight in 8 men (aged 19-46 yr) and 4 women (aged 19-39 yr) to quantitate endogenous GH secretion and half-life 72 h after the prospective, randomly ordered, double blind, and within-subject cross-over administration of pegvisomant (1 mg/…
In this study, Pegvisomant was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pegvisomant.
Report a problemFND-1144320505

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · source ClinicalTrials.gov (opens in a new tab)

Status unknownNot applicableNCT01804413

Pegvisomant With Glucagon Test to Assess for Adult Growth Hormone Deficiency

Oregon Health and Science Universityn = 10Mar 2011 to est. Dec 2013

Adults Growth Hormone Deficiency.

Trial page ClinicalTrials.govUpdated 24 Oct 2013

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:34 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.